Skip to content

German National Registry for NSS

German National Registry for Nephron-Sparing Surgery

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04681690
Enrollment
137
Registered
2020-12-23
Start date
2020-12-15
Completion date
2025-12-31
Last updated
2026-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Neoplasm

Brief summary

The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. Analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.

Detailed description

Today the majority of patients with renal tumors is diagnosed with localized disease amenable to nephron-sparing surgery (NSS). Partial nephrectomy (PN) constitutes the reference standard treatment for small renal masses according to international guidelines. Open PN ist still the predominant apporach in Germany, but the use of minimally-invasive surgery has continously increased over the last decades. Specifically, robotic surgery is on the rise and may facilitate the adoption of a minimally-invasive PN approach even in more complex renal tumours. Real world data on the outcomes of PN according to the surgical approach are limited. Data from cancer registries and health insurance databases usually lack important information an key patient und tumour characteristics, such as tumour complexity. The G-NESS registry database aims at prospectively collecting such clinical and outcome data from patients undergoing PN. Data collection includes perioperative variables on patient characteristics, tumour location and complexity, surgical approach, intra-/postoperative complications, and kidney function. Follow-up based on questionnaires is conducted after predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive information on long-term kidney function, comorbidities, and survival. The information received from the database can help to better define the optimal surgical care for patients with renal masses.

Interventions

OTHERNo intervention, observation only.

Observation only

Sponsors

Association of Urologic Oncology (AUO)
Lead SponsorOTHER
IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)
CollaboratorUNKNOWN

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Written informed consent * Localized renal parenchymal mass amenable to nephron-sparing surgery * Adequate imaging of the abdomen (CT or MR with contrast)

Exclusion criteria

* Patient with (or suspected to have) urothelial cancer of the kidney * Prior nephron-sparing surgery on ipsilateral kidney * metastasized renal cell carcinoma

Design outcomes

Primary

MeasureTime frameDescription
Complication rate60 monthsComplication rate according to Clavien-Dindo in %
Postoperative glomerular inflitration rate60 monthsRate in ml/min.
Survival60 monthsOverall Survival

Countries

Germany

Contacts

STUDY_CHAIRNina Harke, Dr.

MHH

STUDY_CHAIRStefan Siemer, Prof. Dr.

University Saarland

STUDY_CHAIRSteffen Weikert, Prof. Dr.

Vivantes Humboldt-Klinikum

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 27, 2026